December 10, 2025
View Full PaperNivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma
Key Points
- Evaluate the efficacy of nivolumab plus brentuximab vedotin in treating relapsed/refractory diffuse large B-cell lymphoma.
- Analysis of efficacy data from CheckMate 436 trial
- Efficacy data do not support the use of nivolumab plus brentuximab vedotin for R/R DLBCL treatment
Abstract
Overall, the efficacy data from CheckMate 436 do not support the use of nivolumab plus BV for the treatment of R/R DLBCL.